| 张卫丽,高蕴赫,张文静.加味升陷汤联合比索洛尔治疗慢性心力衰竭 99例[J].安徽医药,2026,30(11):2311-2315. |
| 加味升陷汤联合比索洛尔治疗慢性心力衰竭 99例 |
| Effect of modified Shengxian decoction combined with bisoprolol in treating chronic heart failure patients: 99 cases |
| |
| DOI：10.3969/j.issn.1009-6469.2026.11.037 |
| 中文关键词: 慢性心力衰竭 加味升陷汤 比索洛尔 心功能 中医证候疗效 |
| 英文关键词: Chronic heart failure Modified Shengxian decoction Bisoprolol Cardiac function Traditional Chinese medicine syndrome curative effect |
| 基金项目:河北省中医药管理局科研课题计划项目 No.2021391 |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的探讨加味升陷汤联合比索洛尔治疗慢性心力衰竭( CHF)病人的效果。方法采用倾向评分匹配及回顾性队列研究的方法，收集 2021年 3月至 2023年 3月唐山市中医医院 CHF病人 225例，常规西药治疗者 121例，常规西药联合加味升陷汤者 104例，按照 1∶1最邻近匹配法匹配，分成西药组 99例、联合组 99例。比较两组匹配后的中医证候疗效、临床疗效、心功能及心室重构指标、血清心肌标志物以及不良反应发生率。结果联合组中医证候疗效总有效率为 92.93%(92/99)高于西药组的 83.84%(83/99)(P<0.05)；临床疗效总有效率为 89.90%(89/99)，高于西药组的 78.79%(78/99)(P<0.05)。联合组左，心室射血分数( LVEF)、左心室舒张末期容积( LVEDV)、左心室收缩末期容积( LVESV)、 6 min步行试验( 6MWT)、 N末端 B型利钠肽原(NT-proBNP)、超敏心肌肌钙蛋白 Ⅰ(hs-cTn Ⅰ)治疗前后差值均高于西药组，差异有统计学意义( P<0.05)。两组不良反应发生率差异无统计学意义( P>0.05)。结论加味升陷汤联合比索洛尔治疗能有效增强 CHF病人的心功能和运动耐量，改善心室重构，安全性良好。 |
| 英文摘要: |
| Objective To explore the effect of modified Shengxian decoction combined with bisoprolol in treating chronic heart fail-ure (CHF) patients. Methods The clinical data of 225 patients with CHF in Tangshan Traditional Chinese Medicine Hospital fromMarch 2021 to March 2023 were collected by means of propensity score matching and retrospective cohort study. 121 patients weretreated with conventional western medicine and 104 patients were treated with conventional western medicine combined with addedShengxian decoction. The patients were divided into western medicine group (99 cases) and combined group (99 cases) according to 1:1nearest neighbor matching method. The efficacy of TCM syndromes, clinical efficacy, cardiac function and ventricular remodeling in-dexes, serum myocardial markers and incidence of adverse reactions were compared between the two groups.Results The total effec-tive rate of traditional Chinese medicine syndrome in the combined group was 92.93% (92/99), which was higher than that of the west-ern medicine group (83.84% (83/99) (P<0.05); the total effective rate of clinical efficacy was 89.90% (89/99), which was higher than78.79% (78/99) in the western medicine group (P<0.05). The pre-and post-treatment differences of left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), 6-minute walk test (6MWT), N-terminal B-type natriuretic peptide proteins (NT-proBNP), and ultrasensitive cardiac troponin Ⅰ (hs-cTn Ⅰ) in the combination groupwere higher than that in the western medicine group, and the differences were statistically significant (P<0.05). Adverse reactions were not statistically obviously different between the two groups (P>0.05).Conclusion The combination of modified Shengxian decoction and bisoprolol can effectively enhance the cardiac function and exercise tolerance of CHF patients, improve ventricular remodeling,and have good safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
